Kelly Paul Edward
Chief Operating Officer
Kelly Paul Edward has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2025. 1 of those filings fall inside the rolling window. Most recent filing: Nov 6, 2025.
On the most recent filing, Kelly Paul Edward is listed as Chief Operating Officer at RELMADA THERAPEUTICS, INC. Inside the rolling window, Kelly Paul Edward reported 1 open-market purchase totaling $198K in RLMD and no open-market sales.
Companies traded
Other insiders at RLMD
Insider Buying
$198K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Kelly Paul Edward made?
Kelly Paul Edward has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2025.
Which companies does Kelly Paul Edward trade?
Kelly Paul Edward has filed SEC Form 4 disclosures for 1 company, including RLMD.
When was Kelly Paul Edward's most recent SEC Form 4 filing?
Kelly Paul Edward's most recent SEC Form 4 filing on Tracefour is dated Nov 6, 2025.
What is Kelly Paul Edward's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Kelly Paul Edward is listed as Chief Operating Officer.
What is Kelly Paul Edward's total buy and sell value in the current window?
Inside the rolling retention window, Kelly Paul Edward bought $198K and sold $0 based on SEC Form 4 filings.
What was Kelly Paul Edward's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 90,000 RLMD shares on 2025-11-05, worth $198K, per SEC Form 4 filings.